Clinical Trial: Rivastigmine Capsules in Patients With Probable Vascular Dementia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Brief Summary: The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Detailed Summary:
Sponsor: Novartis

Current Primary Outcome: Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD

Original Primary Outcome:

Current Secondary Outcome: 52 week's treatment with rivastigmine on cognition, activities of daily living, behavior and clinical staging in patients with VaD and probable VaD

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: August 11, 2005
Date Started: February 2002
Date Completion:
Last Updated: March 24, 2017
Last Verified: March 2017